Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Deferred Revenue (2019 - 2025)

Immunocore Holdings' Current Deferred Revenue history spans 2 years, with the latest figure at $583000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $583000.0; the TTM value through Dec 2025 reached $583000.0, changed N/A, while the annual FY2025 figure was $583000.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $583000.0 at Immunocore Holdings, roughly flat from $582000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $7.8 million in Q4 2022 and bottomed at $582000.0 in Q3 2025.